advertisement

Topcon

Abstract #26771 Published in IGR 12-3

An overview of satavaptan: A selective V2 receptor antagonist

Farah J; Daifallah S; Zmily H; Ghali JK
Therapy 2010; 7: 409-422


Satavaptan is a new selective V2 receptor antagonist that shares the aquaretic effect of the other arginine vasopressin antagonists. Its usefulness has been demonstrated in the correction of hyponatremia as well as in fluid removal in patients with cirrhosis. In addition, animal studies have suggested promising effects in the treatment of several other conditions, such as polycystic kidney disease, renal cell carcinoma, glaucoma, diabetic nephropathy and urinary tract infections. This article reviews the various animal and human studies that have outlined its potential clinical role and provided direction for further research with this drug.

J. K. Ghali. Detroit Medical Center, Wayne State University, Detroit, MI, United States. jghali@dmc.org


Classification:

11.14 Investigational drugs; pharmacological experiments (Part of: 11 Medical treatment)



Issue 12-3

Change Issue


advertisement

Oculus